Article Sidebar
Published:
Jan 11, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Cirsilineol inhibits the proliferation and migration of endometriotic cells
Abstract
Methods: Human endometriotic epithelial cells 12Z were treated with 5, 10 and 20 μM cirsilineol, respectively. Cell proliferation was evaluated using BrdU incorporation assay whereas wound healing assay was used to investigate cell migration, and cell invasion was assessed by Transwell assay. Cell cycle was investigated using flow cytometry while protein expression and phosphorylation levels of p65 and IκBα were evaluated by Western blot.
Results: Treatment with cirsilineol at either 10 μM or 20 μM resulted in a significant reduction in cell proliferation and cell cycle arrest at the G2/M phase (p < 0.05). Moreover, cirsilineol weakened cell migration and invasion in 12Z cells, but did not alter the expression of p65. However, it significantly downregulated the phosphorylation of p65 and increased the expression of IκBα, while attenuating the phosphorylation level of IκBα (p < 0.05). Furthermore, 5 μM cirsilineol did not show any significant effects on these cellular activities, suggesting the activity of cirsilineol in 12Z cells is dose-dependent.
Conclusion: Cirsilineol inhibits cell proliferation, induces cell cycle arrest, suppresses migration and invasion of endometriotic epithelial cells by regulating NF-κB pathway. Thus, cirsilineol might be a potential therapeutic candidate for endometriosis treatmen
